INTRODUCTION
The major histocompatibility complex (MHC) class II molecules are central in autoimmune processes and are under strict expressional control of the class II MHC transactivator (CIITA, also known as MHC2TA). Rare, recessive loss-of-function mutations in CIITA cause a near complete lack of MHC class II expression and severe immunodeficiency, 1 but more subtle effects could potentially arise with more common variants in this gene. This has been proposed for a single-nucleotide polymorphism (SNP) in the CIITA promoter, rs3087456 A4G (-168 A/G), which has been reported associated with a number of autoimmune diseases, including rheumatoid arthritis (RA) and autoimmune Addison's disease (AAD). [2] [3] [4] [5] However, other association results for rs3087456 have been conflicting, 3, [6] [7] [8] [9] [10] [11] [12] [13] [14] and a recent meta-analysis in RA found no significant association with rs3087456. 15 A possible explanation for this could be that rs3087456 is only an imperfect marker for a real aetiological variant in the vicinity. This was suggested by a fine-mapping study of the CIITA gene in Norwegian AAD patients, where the association with rs3087456 could be explained by a stronger association with the rs8048002 T4C SNP in intron 3 of CIITA. 5 We therefore tested both of these SNPs in the three autoimmune diseases RA, juvenile idiopathic arthritis (JIA) and type 1 diabetes (T1D). In addition, we conducted an updated meta-analysis of the rs3087456 SNP in RA, including four new studies and our own results.
RESULTS

Association tests
Both rs3087456 and rs8048002 were associated with RA in the Norwegian material. Significant association with rs3087456 was restricted to the GG genotype in a recessive genetic model (GG vs GA þ AA, OR 1.50 (95% CI 1.10-2.05), P ¼ 0.0093), whereas rs8048002 with its low minor allele frequency appeared to follow a dominant genetic model (CC þ CT vs TT, OR 1.30 (95% CI 1.03-1.63), P ¼ 0.026; Tables 1 and 2 , respectively). The association with rs8048002 was convincingly replicated in the Swedish RA cohort (OR 1.35 (95% CI 1.09-1.67), P ¼ 0.0056), and results for both SNPs in the combined Norwegian and Swedish RA cohorts withstood correction for multiple testing (rs3087456 OR 1.37 (95% CI 1.11-1.69), P ¼ 0.0030, P corrected ¼ 0.012; rs8048002 OR 1.33 (95% CI 1.14-1.55), P ¼ 3.9 Â 10 À 4 , P corrected ¼ 0.0016; Tables 1 and 2) . No significant association was found between any of the SNPs and JIA or T1D in our materials (P40.091; Tables 1 and 2) , or between rs3087456 and JIA in a meta-analysis combining the results of the current study with two earlier published studies (a total of 812 patients and 2823 controls; P ¼ 0.11 for a dominant model, results not shown). 12, 13 Although a previous meta-analysis of published results for the rs3087456 SNP in RA patients revealed no significant association, 15 four more studies of this SNP have been published since then. 6, 10, 13, 16 Using only the recessive model, which was strongest in both our results and the previous metaanalysis (P ¼ 0. Meta-analysis, fixed effects model; heterogeneity:
for an allelic test) were not available and could therefore not be included in the meta-analysis. 9 However, inclusion of genotype counts estimated from the allelic ratios reported in this study (assuming Hardy-Weinberg equilibrium) gave essentially the same result in the total material (OR 1.15 (95% CI 1.03-1.29), P ¼ 0.016).
Subgroup analyses indicate population dependence To explore the data further, we performed subgroup analyses of cohorts expected to be more homogenous, that is, Scandinavian, British and Spanish patients and controls ( Figure 1 ). This revealed a stronger association of rs3087456 in the combined Norwegian and Swedish cohorts (3551 patients and 4827 controls; OR 1.39 (95% CI 1.16-1.66), P ¼ 3.8 Â 10 À 4 ; no heterogeneity: I 2 ¼ 0%, P ¼ 0.91), whereas none of the other subgroups reached significance (P40.82). Similarly, a meta-analysis of rs8048002, including our results and a single study with British RA patients and controls, 17 revealed a significant association in Scandinavian cohorts only (OR 1.33 (95% CI 1.13-1.55), P ¼ 3.9 Â 10 À 4
; Figure 2 ). This could indicate that these SNP associations are population dependent.
Analyses of shared epitope and anti-citrullinated protein antibodies (ACPA) status Due to the role of CIITA in HLA class II regulation and the potential role in autoimmunity, we also analysed our results with respect to ACPA or shared epitope status in our RA materials. Combined results for the Norwegian and Swedish cohorts (Table 3 and Supplementary Figures 1 and 2 ) showed a more pronounced association with rs3087456 in the subgroup positive for shared epitope (OR 1.58 (95% CI 1.20-2.10), P ¼ 0.0013), and with rs8048002 in ACPA negative patients (OR 1.49 (95% CI 1.21-1.83), P ¼ 1.3 Â 10 À 4 ). However, only the result for rs3087456 and shared epitope was significantly different between the two subgroups (P ¼ 0.046; Table 3 ).
Dependency between associations Linkage disequilibrium (LD) between rs3087456 and rs8048002 indicated some relationship between the RA association with these SNPs (D 0 ¼ 0.98 and r 2 ¼ 0.21 in the Norwegian cohort and D 0 ¼ 0.96 and r 2 ¼ 0.20 in the Swedish cohort). Haplotype analysis also revealed that the minor rs8048002*C allele virtually always appeared together with the more common minor rs3087456*G allele (Table 4) . Moreover, whereas this haplotype appeared susceptible (P ¼ 0.050 and P ¼ 0.0025 in Norwegian and Swedish cohorts), rs3087456*G also occurred on non-risk haplotypes. Conditional regression analyses also suggested dependency between the associations, but could, however, not confirm that the RA association with rs3087456 was dependent on LD with rs8048002 (Supplementary Table 2 ).
The rs6489169 SNP in the neighbouring C-type lectin domain family 16, member A (CLEC16A) gene has previously been reported associated with RA and JIA in our Norwegian materials, 18 but was in weak LD (D'o0.12, r 2 o0.002) with both rs3087456 and rs8048002 in the present materials, indicating that the CIITA associations were independent of this effect. This was also supported by conditional logistic regression analyses (results not shown). Figure 1 . Meta-analysis of rs3087456 GG vs GA þ AA in RA patients and controls. Combined associations were tested using a random effects model. *Controls were constructed from a family material using the affected family-based association control (AFBAC) method, using the two non-transmitted alleles within each family.
DISCUSSION
In this report, we provide confirmatory evidence for a role of CIITA variants in RA. A novel association between RA and the CIITA intron 3 SNP rs8048002 was identified in a Norwegian cohort and replicated in an independent Swedish cohort. In addition, we confirmed earlier reports of an association between the CIITA promoter SNP rs3087456 and RA, both in the combined Scandinavian sample set and in an updated meta-analysis, with a more consistent result in the Scandinavian cohorts. Of the two SNPs, rs8048002 showed a slightly more significant result than rs3087456 in our cohorts (combined P ¼ 3.9 Â 10 À 4 vs 0.0030), and haplotype analyses suggested some dependency of rs3087456 on the association with rs8048002. Although this could not be verified in regression analyses, the same result was observed in a previous study of Norwegian AAD patients, 5 suggesting that rs8048002 is a better marker for a true susceptibility locus in this region. Although CIITA variants are suggested to confer risk for several autoimmune diseases, no association was found for JIA or T1D.
The results for RA are in contrast with several previous reports, in particular studies of British and Spanish RA cohorts. [6] [7] [8] 10, 14, 17 These geographical subgroups also showed clear negative results in our meta-analysis of rs3087456. To our knowledge, no genomewide association study has demonstrated association with the CIITA locus, however, many of the commonly used SNP arrays do not include either of the rs3087456 or rs8048002 SNPs. Isolated reports in most other non-Scandinavian populations have also been negative, 3, 9, [11] [12] [13] 17 although it may be too soon to conclude that these are true negatives until more studies in each population have been performed. Perhaps the most interesting of other positive results for CIITA SNPs in RA is a Japanese study of rs3087456, which showed an association with the GG genotype similar to our study (recessive OR 1.47 (95% CI 1.16-1.87), P ¼ 0.0010), despite the fact that the rs3087456 G allele is the major allele in this population. 2 This result has, however, not yet been tested in an independent Japanese RA cohort. Regardless, these observations suggest that association between RA and the CIITA variants investigated in this paper are population dependent. Although speculative, this could also apply to other autoimmune diseases. Recently, a SNP in CIITA intron 1 (rs4781011 G4T; LD in HapMap CEU with rs3087456 r 2 ¼ 0.96; with rs8048002 r 2 ¼ 0.18) was associated with ulcerative colitis in a combined genome-wide association study of North American and Swedish patients, with the strongest result for the Swedish cohort and positive replication in Dutch but not Italian patients. 19 As expected from the high LD with rs3087456, however, this SNP was not associated with RA in a recent British study. 17 Possible explanations for such population dependency include phenotypic diversity between patient cohorts, which may function as a confounder. In particular, associations in our cohorts appeared to be more pronounced with rs3087456 in the shared epitope positive subgroup and with rs8048002 in the ACPAnegative patients. These two subgroups were relatively larger in our cohorts than in many of the studies that report no associations, with some of the more noticeable differences to Figure 2 . Meta-analysis of rs8048002 CC þ CT vs TT in RA patients and controls. Combined associations were tested using a random effects model. Supplementary Figures 1 and 2 .
the Spanish cohorts (Supplementary Table 3 ). However, information on these variables from the individual studies was too sparse to perform a proper covariate meta-analysis. Moreover, our results should be interpreted with caution, as the relation to shared epitope and ACPA status differed for the two SNPs, despite signs of association dependency. A more likely scenario is perhaps differences in genetic population structure, for example, that none of the investigated SNPs are primary loci, and that one or more true functional variants are in strong LD with these SNPs only in certain populations. In addition, akin to what has been observed for some disease associated variants of the HLA-DRB1, PTPN22 and CCR5 genes, [20] [21] [22] the true aetiological variants may also be less frequent or even absent in certain populations. This would be especially relevant if the true aetiological CIITA variants are rare.
In conclusion, our results provide support for an involvement of one or more CIITA gene variants in RA, but imply that these associations are population dependent. No association with JIA or T1D was found. Still, additional studies, preferably involving finemapping or re-sequencing and including less well-characterised populations, are needed to establish the true role of CIITA in RA and autoimmunity.
PATIENTS AND METHODS
Study populations
We genotyped 819 RA, 524 JIA, 1211 T1D patients and 2149 control samples (all Norwegian Caucasians), as well as a Swedish replication cohort with 2503 RA patients and 1416 controls.
All RA patients were diagnosed according to the American College of Rheumatology criteria. 23 Norwegian RA patients were from the Oslo RA Registryand the European Research on Incapacitating Disease and Social Support cohorts, 24, 25 whereas Swedish RA patients were recruited through the Epidemiological Investigation of Rheumatoid Arthritis (EIRA) study. 26, 27 Status for ACPA and shared epitope in these cohorts are given in Supplementary  Table 3 . ACPA concentrations were measured with an ELISA kit assay (INOVA Diagnostics, San Diego, CA, USA) in Norwegian RA samples and with an Immunoscan RA (Mark 2) enzyme-linked immunosorbent assay (EuroDiagnostica, Malmö , Sweden) in Swedish RA samples. Positivity for ACPA was defined at levels Z25 U ml À 1 , and shared epitope positivity was defined as the presence of at least one of the following HLA-DRB1 alleles: *01 except *0103; *04 except *0402; *10 and *14. Patients and clinical subgroups of JIA (n polyarthritis ¼ 127; n oligoarthritis ¼ 215; n enthesis-related arthrits ¼ 72; n psoriatic arthritis ¼ 43; n undifferentiated arthritis ¼ 38; n systemic arthritis ¼ 29) were classified according to the International League of Associations for Rheumatology criteria. 28 The T1D sample set consisted of children predominantly younger than 15 years at age of onset, reported to the Norwegian Childhood Diabetes Registry according to the EURODIAB criteria. 29 Norwegian controls were from two independent cohorts, 1029 blood donors recruited at Oslo University Hospital, Ullevål (Control set #1) and 1120 individuals from the Norwegian Bone Marrow Donor Registry, Oslo University Hospital, Rikshospitalet (Control set #2). Swedish control samples (n ¼ 1416) were population-based random samples matched to the RA patients and recruited through the EIRA study. 26, 27 Informed consent was obtained from all participants or their parents in compliance with the latest version of the Helsinki Declaration. Regional Ethical Committees in both Norway and Sweden have approved the study.
Genotyping
Whole genome amplification of DNA (GenomiPhi DNA Amplification Kit, GE Healthcare, Chalfont St Giles, UK) was performed before genotyping in all Norwegian sample sets except Control set #1. Whole genome amplified DNA has been validated extensively for the use of SNP genotyping. 30 Genotyping for rs3087456 and rs8048002 was performed with TaqMan SNP Genotyping Assay ID C_381748_10 and C_15793789_10 (Applied Biosystems, Foster City, CA, USA). All plots were inspected manually after automatic calling. The call rate was 495% for both SNPs in all materials, no significant differences were detected between the two Norwegian control populations, and no significant departures from Hardy-Weinberg equilibrium were observed in any of the control materials (P40.05). Genotyping of HLA-DRB1 in the Norwegian RA patients and Control set #2 was done by sequence-based genotyping, 31 Control set #1 by a PCR-based sequencespecific oligonucleotide probe system, 32 and Swedish samples by single specific primer (SSP)-PCR (Olerup SSP, Saltsjö baden, Sweden).
Literature search
A comprehensive search of the current peer-reviewed medical literature was performed in June 2011 using PubMed and the search string ((CIITA(All Fields) OR MHC2TA(All Fields) OR C2TA(All Fields) OR NLRA(All Fields) OR "MHC class II transactivator protein"(Substance Name)). Titles and abstracts (n ¼ 759), and where needed full-text articles, were reviewed for relevance by one of the authors (MCE).
Statistical analyses
A priori power calculations were performed with R version 2.12.2 and the bpower function in the R Hmisc package (http://www.stat.ucl.ac.be/ ISdidactique/Rhelp/library/Hmisc/html/bpower.html). As detailed in Supplementary Table 1, we had 487% power in all patient materials to detect an allelic effect with OR 1.79 for rs8048002 (from Skinningsrud et al.
5
), but only 28-53% power for an allelic effect with OR 1.17 for rs3087456 (from Swanberg et al. 4 ). Nevertheless, we considered genotyping to be justified by the possibility for meta-analyses. Associations between genotypes and disease status were calculated using PASW Statistics v18.0.1 (SPSS Inc., Chicago, IL, USA). Allelic association tests and regression analyses were performed using PLINK v1.07 (http://pngu.mgh.harvard.edu/purcell/plink/), haplotype tests were performed with Unphased v3.1.4 (http://unphased.sourceforge.net/). All joint analyses of the Norwegian and Swedish cohorts, as well as other meta-analyses, were performed with Review Manager v5.1.2 (The Cochrane Collaboration, Copenhagen, Denmark), 33 using a Mantel-Haenszel (M-H) fixed effects model for analyses involving Scandinavian cohorts only, and a M-H random effects model to account for heterogeneity when including non-Scandinavian cohorts. Meta-analyses were performed using the genetic model with the best P-value in the Norwegian material (recessive model for rs3087456 in RA, dominant model for rs3087456 in JIA and for rs8048002 in RA). As we considered this a replication study, including just two markers, P-values were only corrected for multiple testing in the association tests of the combined Norwegian and Swedish cohorts (Bonferroni correction for four tests, two SNPs times two patient cohorts).
Data for rs3087456 and rs8048002 has been published earlier for Control set #1 in a study of AAD patients. 5 In the Swedish cohort, results for rs3087456 in 1288 of the patients and 709 of the controls was reported in the original CIITA study from 2005, 4 and we therefore report results for the new samples (1212 patients and 706 controls) separately in Table 1 .
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